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Purpose: To evaluate levels of 37 native pathway proteins of the vitreous proteome from a subset of wet age-related
macular degeneration (AMD) patients with and without subretinal fluid (SRF).
Methods: A total of 62 consecutive samples were aspirated from 12 patients with AMD, six who had SRF at baseline,
and six who did not have SRF at any point during the study. Vitreous levels of the 37 native pathway proteins were
analyzed in these patients using reverse phase protein microarray technology. At each visit, at which the 62 samples were
taken, SRF and central retinal thickness were measured. These values were then compared to the relative intensity level
of the 37 proteins screened.
Results: In the subset of AMD patients with SRF, the average matrix metalloproteinase 9 (MMP-9), interleukin (IL)-12,
Abelson murine leukemia viral oncogene homolog 1 (cABL) Thr735, heme oxygenase-1, Musashi, platelet-derived
growth factor receptor beta Tyr751 (PDGFRβ), IL-8, and BCL-2 associated death promoter (BAD) Ser112 levels in the
vitreous were found to be significantly different with a 21%–82% increase in expression compared to those without SRF
(p<0.0001). Within the SRF group, there was a positive correlation between the vitreous MMP-9 levels and the SRF level.
MMP-9 levels in the vitreous proteome varied with the level of SRF but not retinal edema. Compared to patients without
SRF, the patients with initial SRF had persistent or progressive disease.
Conclusions: This is the first prospective case series sequentially monitoring the vitreous proteome in patients with wet
AMD. The results suggest that MMP-9 is a proteomic biomarker of SRF accumulation, separate from macular edema.
Exudative  or  wet  age-related  macular  degeneration
(AMD) is a complex disease. The heterogeneity of disease
expression  and  the  differences  in  patient  response  to
antiangiogenic  bevacizumab  or  ranibizumab  treatment
suggests that vascular endothelial growth factor (VEGF) is
unlikely to be the only protein of interest in this disease. In
fact, studies have shown proteins such as VEGFR2 Y1175 and
Y951 [1], transforming growth factor-beta 1 and monocyte
chemotactic  protein-1  [2],  and  C-reactive  protein  and
interleukin-6 (IL-6) [3], may play a role in determining the
clinical  course  of  AMD.  These  studies  imply  that  the
determining factors of AMD may vary from patient to patient
and investigating the vitreous proteome for a wide range of
potential biomarkers will be integral in defining the biologic
pathways that are important in the disease.
Previous work has demonstrated the safety and efficacy
of taking small vitreous aspirations in an in-office setting for
use  with  reverse  phase  protein  microarray  (RPPM)
technology for analyzing the samples against a wide array of
pathway proteins [1,4]. Here, a pilot study was designed to
measure the vitreous levels of 37 activated or native pathway
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proteins representing angiogenesis, apoptosis, inflammation,
and hypoxia/oxidative stress pathways against quantifiable
clinical findings in AMD, including central retinal thickness
(CRT) and subretinal fluid (SRF). SRF and CRT levels were
chosen  for  study  because  significant  differences  among
patients are regularly observed. Multiple sequential vitreous
aspirates  (3–9)  were  taken  from  each  study  patient  and
analyzed to understand if a correlation exists with levels of
SRF and CRT. The results of this study demonstrate that
matrix  metalloproteinase  9  (MMP-9)  is  significantly
associated with the development of SRF in AMD patients.
Since MMP-9 expression correlates with levels of SRF in
retinal detachment [5,6], this analysis may lead to a unifying
understanding of why SRF accumulates.
METHODS
This prospective series included 62 consecutive samples from
patients with exudative AMD who had undergone in-office
diagnostic  vitreous  sampling  before  anti-VEGF  agent  or
corticosteroid  was  intravitreally  injected  at  multiple  time
points [4]. Twelve patients with AMD were enrolled: six with
SRF and six with retinal thickening but no SRF (see Table 1).
This research study and vitreous aspiration procedure has
institutional  review  board  approval  (Western  Institutional
Review  Board,  Olympia,  WA)  and  is  Health  Insurance
Portability and Accountability Act–compliant with written
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1658informed consent received from all study patients. Patients
were selected for this study based on a set of inclusion and
exclusion  criteria.  The  inclusion  criteria  included  the
following:  1)  Patients  with  exudative  AMD  that  required
intravitreal  medication  injection  (anti-VEGF  or
corticosteroid)  and  2)  who  consented  to  undergo  vitreous
sampling. The exclusion criteria were as follows: 1) Patients
unwilling  or  unable  to  consent  to  study  or  follow-up,  2)
ophthalmic surgery within the last three months, 3) active
intraocular  inflammation,  and  4)  recent  cerebral  vascular
accident or myocardial infarction.
At  each  visit,  study  patients  received  a  standard
examination that included a detailed medical history, ETDRS
best-corrected  visual  acuity,  intraocular  pressure,  and  a
dilated retinal exam. All patients had intravenous fluorescein
angiography,  indocyanine  green  angiography,  and  optical
coherence tomography (Spectralis HRA+OCT, Version 5.3.3;
Heidelberg Engineering, Heidelberg, Germany), at baseline
and every subsequent visit. If SRF or retinal thickening was
present,  patients  underwent  diagnostic  vitreous  sampling
(DVS) followed by an intravitreal injection of an anti-VEGF
agent or corticosteroid agent. Patients with SRF were assigned
to Group 1, while patients with retinal thickening without SRF
were labeled Group 2 (see Table 2 and Table 3). Patients were
followed at monthly intervals.
Spectral domain OCT images were obtained using the
standard volume scan algorithm that acquires 19 horizontal
B-scans of the macula (7 µm resolution). All subsequent scans
TABLE 1. PATIENT DEMOGRAPHICS.
Number of patients 12
Average age 78
Age range 66–90
Sex
Male 4
Female 8
Total vitreous samples 62
Avg per patient 5.1
Range (3–9)
Avg follow-up (days) 165
Range (days) (70–279)
TABLE 2. GROUP 1 (SUBRETINAL FLUID) DEMOGRAPHICS.
Patient Age Initial VA Final VA Study vitreous
sample/injections
1 85 20/63 20/40 4
2 70 20/50 20/20 7
3 66 20/100 20/100 7
4* 90 20/50 20/80 7
5* 63 20/100 20/63 6
6* 73 20/63 20/32 8
        * Patient 4 and 5 had intravitreal triamcinolone, at visit 8 and 6 respectively. Patient 6 was switched to ranibizumab on visits
        6–7. All other injections were bevacizumab 0.05 ml/1.25 mg.
TABLE 3. GROUP 2 (NO SUBRETINAL FLUID) DEMOGRAPHICS.
Patient Age Initial VA Final VA Study vitreous samples/
injections
7 80 20/160 20/100 3
8 88 20/100 20/80 4
9 86 20/200 20/200 4
10 74 20/80 20/63 3
11 82 20/800 20/640 3
12 82 20/40 20/40 4
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1659were registered to the initial scan (reference scan) allowing
accurate  point-to-point  measurements  on  follow-up.  The
caliper tool allowed the SRF height to be measured (distance
between the hyper-reflective band corresponding to the inner
aspect of the retinal pigment epithelium [RPE] to the hyper-
reflective  band  corresponding  to  the  photoreceptor  inner
segment junction and outer segments) at exact locations on
follow-up. In Group 1, the point of the greatest linear height
of SRF was measured and followed at each time interval. If
SRF resolved and a new area of fluid developed, the new
location was followed (two patients). In both groups, a linear
calculation of retinal thickness was performed at the site of
SRF measurement or at the site of greatest thickening for
patients  without  sub-retinal  fluid.  Spectralis  HRA+OCT
software’s automated retinal thickness algorithm was used for
thickness measurements. Each measurement was inspected to
ensure that the appropriate retinal boundaries were marked
(see Appendix 1).
DVS  [4]  was  performed  by  taking  a  small  vitreous
aspirate before an injection of bevacizumab 0.05 ml/1.25 mg
(Avastin; Genentech, South San Francisco, CA), ranibizumab
0.05  ml/1.25  mg  (Lucentis;  Genentech),  or  triamcinolone
Figure  1.  Validation  of  matrix  metalloproteinase  9  (MMP-9)
antibody (Cell Signaling Cat# 3852, Lot#2) via western blot. The
molecular weight of MMP-9 is 84, 92 kDa. Lanes 1–3 go Left to
Right. Lane 1: is a Magic Mark Western Standard (Cat # LC5602,
Life Technologies) molecular weights ranging from 20 to 220 kDa.
Lane 2, shows the validation of the MMP-9 antibody, using human
endothelial cell lysates (BD Cat# 611450, Lot: 86722). Lane 3 shows
is a negative control loaded with BSA (BSA; Thermo Fisher Product
# 23209).
acetonide  0.10  ml/4  mg  (Kenalog;  Bristol-Meyer-Squibb,
New York, NY). Vitreous samples were obtained by using a
standard  technique  on  all  patients  as  follows:  Topical
anesthesia was achieved by instilling topical lidocaine gel 2%
(Xylocaine; AstraZeneca LP, Wilmington, DE) followed by
placement of a soaked cotton-tip applicator (lidocaine 4%
solution; Roxane Laboratories, Columbus, OH) in the inferior
temporal quadrant. Using sterile gloves, a sterile lid speculum
was placed followed by a drop of Betadine 5% (Alcon, Fort
Worth,  TX).  Immediately  following,  a  25  gauge  needle
(Terumo Needle; Terumo Medical Corporation, Elkton, MD)
was placed via the pars plana approach into the mid-vitreous
cavity, and 0.05 to 0.10 ml of vitreous fluid was aspirated into
a 1 ml syringe (PrecisionGlide; Becton Dickinson, Franklin
Lakes, NJ). After the needle was removed, a 30 gauge needle
(PrecisionGlide; Becton Dickinson) was introduced into the
same  location  and  the  injection  performed.  Intraocular
pressure was measured only if a vitreous sample was not
obtained  (“dry  sample”).  After  injection,  the  patient  was
discharged with post-injection warnings and instructions to
use  a  fourth-generation  fluoroquinolone  antibiotic  drop
(moxifloxacin or gatifloxacin) four times a day for 5 days.
Patients  were  educated  regarding  the  warning  signs  that
require  immediate  evaluation,  including  pain,  decreased
vision, loss of peripheral vision, redness, or sensitivity to light.
Patients were followed at intervals of 1 month. Safety and
adverse events were documented at all follow-up visits using
a  standardized  history  questionnaire  completed  by  the
examining physician.
Vitreous samples were analyzed with RPPM technology
as follows: 37 antibodies to proteins known to be important
in angiogenesis, proliferation, inflammation, and oxidative
stress pathways were selected and validated in-house with the
western  blot  technique  (see  Appendix  2).  The  validated
antibody blot for MMP-9 can be seen in Figure 1. The total
protein concentration of each vitreous sample was measured
spectrophotometrically  with  the  Bradford  method.  Each
sample was diluted in extraction buffer (45% T-Per; Pierce,
Indianapolis, IN), 10% T-Cep (Fisher Scientific, Fair Lawn,
NJ),  and  45%  2X  SDS  Tris-glycine  loading  buffer
(Invitrogen, Carlsbad, CA) to equalize the total protein loaded
to 0.1 μg/ml. The samples were printed on glass nitrocellulose
coated array slides (FAST slides, Whatman, Florham Park,
NJ)  using  an  Aushon  2470  arrayer  (Aushon  Biosystems,
Burlington, MA) with 350 μm pins. Samples were set up to
be printed in duplicate dilution curves representing the neat,
1:2,  1:4,  and  1:8  dilutions.  For  quality  control  purposes,
control  cell  lysates  prepared  from  A431±  EGF,  HeLa
±Pervanadate, human endothelial cells (Becton Dickinson,
Franklin Lakes, NJ), and BSA were printed on each array in
the same manner, including an eight-point dilution curve from
neat to 1:128. The arrays were stored with desiccant (Drierite;
W.A.  Hammond,  Xenia,  OH)  at  −20  °C  before
immunostaining [1]. Immunostaining was done following the
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primary antibodies (Appendix 2) and biotinylated secondary
antibodies using the Dako autostainer and CSA staining kit
(Dako, Fort Collins, CO).
Spot intensity analysis was done in the same manner as
[7] using ImageQuant (v5.2; GE Healthcare, Piscataway, NJ)
to capture the intensity of every spot on the array. The raw
spot intensity data were then entered into Microsoft Excel
(Microsoft,  Redmond,  WA)  for  normalization,  which
includes  ensuring  the  duplicate  spots  are  within  10%
coefficient of variation (CV) of each other, averaging the
duplicate spots and performing a curve fitting analysis to
determine the dilution point with the best signal to noise ratio.
This  normalization  process  leads  to  a  single  protein
expression value for each sample on the array that represents
the relative intensity (RI), which can be referenced to all other
samples on the array and between arrays [7].
Statistical analyses were performed using SAS Version
9.1.3 (SAS Institute, Cary, NC) and Prism 5.0 (GraphPad, La
Jolla, CA). A t test and repeated measures ANOVA were used
to compare the vitreous protein levels between the two groups
of patients with AMD, and to ensure that patient clustering
did not affect the outcome of the t test, a regression model
using  group  clustering  was  applied.  Receiver  operator
characteristic  (ROC)  analyses  were  also  calculated  to
understand  if  the  analytes  could  significantly  determine
differences  between  the  SRF  and  no  SRF  groups.  The
correlation of each vitreous analyte to the subsequent SRF
level was done via Pearson’s correlation coefficients analysis.
Figure 2. Matrix metalloproteinase 9 (MMP-9) expression in the
vitreous is predictive of subretinal fluid (SRF) accumulation . Here
it can be seen that when MMP-9 expression levels are below 1.0
patients generally have lower levels or no SRF accumulation, but
when MMP-9 levels go above 1.0, patients have higher levels of SRF
accumulation.
RESULTS
This study analyzed 62 sequential samples aspirated from 12
patients with exudative AMD being treated with intravitreal
therapies. Group 1 was composed of six patients with a total
of 41 samples from patients who had baseline SRF, while
Group 2 was also composed of six patients with a total of 21
samples from patients who had no SRF throughout the entire
treatment (Appendix 1). The protein expression levels were
measured for all samples in Groups 1 and 2. Of the 37 proteins
screened, eight were significantly different between Group 1
and 2 using both a t test and a repeated measures ANOVA (see
Table 4 and Table 5).
Vitreous levels of MMP-9 were the most significantly
different between Group 1 and 2. The MMP-9 value for Group
1 (with SRF) had an average vitreous expression level of 1.267
RI,  which  is  82.05%  higher  than  the  average  MMP-9
expression level of 0.2473 RI in Group 2 (no SRF; p≤0.0001).
A regression model, which considered clustering that could
occur for each patient, was applied to these data, and the
results validate the significant difference between the mean
MMP-9 values for Groups 1 and 2 (p=0.0005). As shown in
Table 4, MMP-9 has the most significant difference between
Groups 1 and 2, yet al.l significant proteins move higher when
SRF is present.
MMP-9 showed the most significant changes, so it was
studied  further  to  understand  how  the  expression  levels
correspond to patient SRF levels. These MMP-9 results for
Groups 1 and 2 were split into two expression level groups,
and the mean SRF level for each group was calculated (Figure
2). When MMP-9 levels were below 1.0 RI, the average SRF
was 36.92 µm, but when the MMP-9 level was above 1.0 RI,
the average SRF level increased to 145.56 µm (p≤0.0001). To
visualize trends in the data, a graphical representation (as
shown in Figure 3) illustrates the mean vitreous MMP-9 levels
for each patient in Groups 1 and 2. This shows that the patients
who had no SRF had much lower MMP-9 expression, and
further suggests an association between MMP-9 levels and
SRF accumulation in patients with AMD.
Pearson’s  correlation  analyses  were  calculated  to
determine if the SRF levels from Group 1 correlate with their
corresponding MMP-9 levels. The results show a positive
correlation between SRF levels and vitreous MMP-9 levels
for each Group 1 SRF patient, which ranged from 0.1540 to
0.9857. Figure 4 illustrates these findings, by showing how
MMP-9 levels reflect and track SRF accumulation in each
patient.  The  correlation  between  MMP-9  levels  and  SRF
accumulation may suggest a possible prognostic ability for
MMP-9 in patients with AMD, and other retinal diseases
affected by SRF accumulation. To further explore this idea, a
ROC analysis was completed to test the capability of MMP-9
to detect differences between Group 1 and Group 2 (Figure
5).  This  analysis  revealed  that  MMP-9  specifically  and
sensitively distinguished the difference between Group 1 and
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16612  (area  under  the  curve=0.843,  p≤0.0001),  further
demonstrating  the  strong  difference  in  MMP-9  between
patients who have SRF and those who do not.
Each of the other seven significantly changed proteins
between Group 1 and Group 2 were analyzed using Pearson’s
correlation analysis to determine if the Group 1 patients, with
SRF accumulation, showed a significant relationship to the
expression  levels.  Unlike  MMP-9,  which  had  positive
correlations with SRF levels in each patient, IL-12, cABL
T735, heme oxygenase-1, Musashi, platelet-derived growth
factor receptor beta (PDGFR beta) precursor Y751, IL-8, and
BAD Ser112 had positive and negative correlations; therefore,
we are unable to propose a connection between SRF and
protein expression levels for these proteins (Table 6).
Retinal thickness was measured for each patient in this
study, and the average thickness for Group 1 was 216 microns
(range 170–309 µm) while Group 2 was 485 microns (range
297–779  µm).  After  intravitreal  treatment  (anti-VEGF  or
triamcinolone), the final average thickness for Group 1 was
264 microns (196–422 µm) versus 243 microns (120–318 µm)
for Group 2. All patients except one in Group 2 had complete
resolution  of  their  initial  edema.  No  strong  correlations
TABLE 4. T-TEST RESULTS SHOWING THE PROTEINS WITH SIGNIFICANTLY DIFFERENT LEVELS BETWEEN GROUP 1 AND GROUP 2.
Protein p-value Percent difference
MMP-9 p<0.0001 82.1% higher in Group 1
IL-12 p=0.0018 33.5% higher in Group1
cABL T735 p=0.0040 30.6% higher in Group 1
Heme Oxygenase-1 p=0.0064 26.2% higher in Group 1
Musashi p=0.0175 45.9% higher in Group 1
PDGFRβ Y751 p=0.0238 21.3% higher in Group 1
IL-8 p=0.0355 23.0% higher in Group 1
BAD S112 p=0.0478 23.4% higher in Group 1
        The significant results from t-test of each protein screened for group1 (patients with subretibnal fluid [SRF]) versus group 2
        (patients with no SRF). Eight proteins (listed below) had a significant elevation in expression level in the group 1 patients, with
        matrix metalloproteinase 9 (MMP-9) showing the most significant change.
TABLE 5. REPEATED MEASURES ANOVA RESULTS SHOWING THE PROTEINS WITH SIGNIFICANTLY DIFFERENT LEVELS BETWEEN GROUP 1 AND
GROUP 2.
Protein p-value
MMP-9 p<0.0001
IL-12 p=0.0007
cABL T735 p=0.0018
Heme Oxygenase-1 p=0.0318
Musashi p=0.0127
PDGFRβ Y751 p=0.001
IL-8 p=0.0338
BAD S112 p=0.0084
        The Results of a repeated measures ANOVA, showing that the same eight proteins as in Table 4, are significantly different when
        comparing group 1 and group 2 patients.
TABLE 6. PEARSON’S CORRELATION RESULTS FOR IL-12, BAD SER 112, CABL THR 735, HEME OXYGENASE-1, IL-8, MUSASHI AND PDGFRΒ Y751.
Patients IL-12 c-Abl
T7hr35
HemeOx-1 Musashi PDGFRβ
Y751
IL-8 Bad Ser112
Patient 1 0.94868 −0.10541 −0.10541 0.948683 0.632456 0.948683 0.105409
Patient 2 0.71428 0.50000 0.714286 0.071429 0.142857 0.678571 0.178571
Patient 3 −0.21429 −0.53571 −0.60714 −0.10714 0.357143 −0.21429 −0.35714
Patient 4 0.25150 −0.35929 −0.32336 0.646718 0.850315 0.514979 0.083834
Patient 5 0.60000 0.485714 0.60000 0.657143 0.657143 0.60000 0.60000
Patient 6 −0.43377 −0.44582 −0.0482 −0.0482 −0.26508 −0.40967 −0.45786
        The correlation coefficients are reported for each.
Molecular Vision 2012; 18:1658-1667 <http://www.molvis.org/molvis/v18/a171> © 2012 Molecular Vision
1662between vitreous MMP-9 levels and retinal thickening were
observed.
DISCUSSION
Exudative  AMD  is  a  complex  disorder  with  each  patient
having  individual  pathologic  components  occurring  at
different times and with different sequences. We are currently
learning about genes that may be associated with AMD and
still need to determine how to detect when these genes become
active [8]. Vitreous proteomics can now be performed as an
in-office procedure, and biomarkers can be measured over
time  so  that  disease  progression  may  be  predicted  [1,4].
Vitreous proteomics provides a promising opportunity to map
the activity of pathways active in each individual patient so
that  treatment  can  be  optimized  and  a  new  approach  to
treatment can be developed. Our pilot study was designed to
measure the vitreous levels of 37 native pathway proteins
representing  angiogenesis,  apoptosis,  inflammation,  and
hypoxia/oxidative  stress  pathways  against  quantifiable
clinical findings in AMD including CRT and SRF. Multiple
sequential vitreous aspirates (3–9) were taken from each study
patient and analyzed to understand if a correlation exists with
levels of SRF and CRT. The results suggest that MMP-9 is a
potential biomarker in the development of SRF in patients
with AMD. Though SRF accumulation can be seen via OCT,
elucidating its biologic mechanisms will have much greater
implications for future research. Further, this type of research
could initiate predictive treatment capabilities within ocular
medicine in the future.
MMPs  are  a  complex  family  of  enzymes  capable  of
degrading the major components of the extracellular matrix
(ECM) and are associated with processes involving ECM
remodeling,  development,  angiogenesis,  and  inflammation
[9]. MMP-9 is also known as gelatinase B due to its specificity
for type IV collagen and its role in breaking down basement
membranes  [9].  There  is  evidence  suggesting  MMP-9  is
associated with components of the Bruch’s membrane-RPE
complex and is secreted by retinal pigment epithelial cells,
and secretion of MMP-9 may result in defects in Bruch’s
[10]. Such a defect in Bruch’s membrane may result from the
overexpression of MMPs in the outer retinal complex and
likely  enables  various  events,  possibly  including  the
development of SRF and facilitating the cascade of choroidal
neovascularization.  Although  the  complete  role  of  these
factors has not yet been elucidated, they have been associated
with  basal  laminar  deposits  [10],  laser-induced  choroidal
neovascularization  [11–13],  and  choroidal  neovascular
membranes associated with AMD [11,14]. MMPs have also
been associated with RPE cells and the inter-photoreceptor
matrix [10,15].
Recent reports have found that levels of MMP-9 in SRF
and  vitreous  correlate  with  the  extent  and  duration  of
rhegmatogenous retinal detachment [5,6]. The results from
these reports suggest that increased vitreous MMP-9 may play
a  role  in  conditions  where  the  RPE-neurosensory  retina
interface has been compromised. This reaction to increased
MMP-9  expression  is  logical  because  as  membranes  and
collagen are being broken down, areas are left open for fluid
accumulation and new blood vessel growth. Currently, we can
only speculate what role MMP-9 might play in forming SRF.
Since  what  causes  the  development  of  SRF  is  not  yet
understood, an array of proteins might be involved in the
normal attachment of the outer retina segments to the RPE.
Our study builds on past findings by showing that levels
of  MMP-9  in  the  vitreous  of  patients  with  AMD  are
significantly associated with the accumulation of SRF. These
Figure 3. Matrix metalloproteinase 9 (MMP-9) expression differences between patients with SRF versus patients with no subretinal fluid
(SRF). The MMP-9 mean expression level (±SD) is shown for each patient in this study. The Group 1 (Patients with SRF) graph shows that
most patients have a mean MMP-9 expression level greater than 1.0. Whereas the Group 2 (Patients with NO SRF) graph shows that all
patients have a mean MMP-9 expression level much lower than 1.0.
Molecular Vision 2012; 18:1658-1667 <http://www.molvis.org/molvis/v18/a171> © 2012 Molecular Vision
1663results  also  help  further  define  the  biologic  mechanisms
involved in the disease. Although each sample used in this
study was screened against 37 antibodies to growth factors,
cytokines, and other proteins, MMP-9 had the most significant
findings in this cohort of patients (see Table 4). Between the
two groups of patients, the mean vitreous levels of MMP-9
were statistically higher in patients with SRF (p<0.0001). In
addition, we observed a positive correlation between vitreous
levels of MMP-9 and the height of SRF, suggesting that a
direct  relationship  between  disease  activity  and  vitreous
MMP-9 may be present (see Figure 4). No such correlation
with CRT was observed. Data shown in Figure 4 shows that
elevation of MMP-9 preceded elevation of SRF. This suggests
that MMP-9 levels may have some prognostic significance
clinically.  The  patients  in  Group  1  with  higher  vitreous
MMP-9 expression levels and higher SRF exhibited more
persistent  disease  compared  with  patients  without  SRF
(Figure 3). In Group 1, only one patient (Patient 1) had full
Figure 4. Matrix metalloproteinase 9 (MMP-9) tracks patient subretinal fluid (SRF) levels. The MMP-9 and SRF levels for patients 1–6 are
plotted for each patient treatment visit. These graphs demonstrate how MMP-9 expression levels in the vitreous track the rise and fall of SRF
in each patient over time.
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1664resolution of SRF, while all others continued to have elevated
SRF levels. Vitreous levels of MMP-9 might be able to predict
levels of SRF as is suggested by the results from the ROC
curve analysis (see Figure 5). To validate this claim, a true
prediction model will need to be developed as more data are
collected.
With regard to retinal thickening, an additional finding
was observed in Group 1. In this group there was minimal
retinal thickening overlying areas of SRF. In addition, retinal
thickness  remained  relatively  constant  despite  significant
changes  in  SRF  levels  (Appendix  1).  These  observations
combined  with  the  vitreous  MMP-9  data  may  suggest  an
alternative  biologic  pathway  for  retinal  edema  and  SRF
development  that  is  perhaps  partly  mediated  by  MMP-9
activity. Future studies of other retinal conditions such as
central serous retinopathy will determine if there is also a
correlation between MMP-9 and SRF.
A  limitation  of  the  current  study  is  the  small  patient
population size. However, we analyzed 62 total samples with
three to nine samples per eye during the course of disease. To
the best of our knowledge, this is the largest group yet reported
of in-office vitreous samples at multiple time points during a
treatment  course.  Previous  studies  used  surgical  samples;
however, one is unable to track a patient’s response over
multiple time points using vitrectomy samples as a guide. The
advantage of this study was the ability to monitor individual
Figure 5. Sensitivity and specificity of matrix metalloproteinase 9
(MMP-9)  association  with  subretinal  fluid  (SRF)  accumulation.
Receiver operator characteristic (ROC) curve analysis demonstrates
MMP-9 to have a significant ability to distinguish patients who have
SRF from patients who do not have SRF accumulation, with an area
under curve (AUC) of 0.8492 and a p-value of <0.0001. This data
could be used to determine a threshold level of MMP-9 that would
be indicative of SRF accumulation, and possible worsening of AMD
pathology.
patients’ proteomic response at multiple time points while
being treated for wet AMD with intravitreal therapies. We
hope that in the future as more research is completed, in-office
vitreous  diagnostics  will  enable  the  physician  to  better
understand disease and predict future clinical course. Surely,
this would be a useful advancement toward individualized
treatment plans.
Conclusion: This pilot study has shown that in a small
subset  of  patients  with  different  morphologic  forms  of
exudative AMD (SRF, CRT), patients with subretinal fluid
have significantly higher vitreous levels of MMP-9 versus
those with only retinal thickening. A positive correlation with
the vitreous level of MMP-9 and the level of subretinal fluid
was  observed  and  shown.  Larger  studies  including  more
patients who have had DVS sampling will be helpful to further
assess the relationship between MMP-9 and other vitreous
proteins with SRF levels in patients with wet AMD and other
neovascular retinal diseases.
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